Indian CDMOs poised for high-teens growth as US Biosecure Act nears law

• US Biosecure Act, part of the NDAA, passed the House and is moving to the Senate, expected to be enacted by end of 2025.
• Macquarie anticipates the Act will accelerate growth for Indian CDMOs, projecting high-teens CAGR over the next five years.
• Indian CDMOs are well-positioned for small-molecule opportunities, though revenue contributions from new projects will have a 12-24 month lag.
• The domestic CDMO market is estimated to expand from $7 billion to $20 billion by 2030, with Divi's Labs and Syngene as Macquarie's preferred picks.
• Sai Life Sciences CFO confirms the Biosecure Act is positive for Indian CDMOs, expecting stronger performance in the coming years.

Why It Matters: US Biosecure Act could significantly boost Indian CDMO companies' growth.